nintedanib inhaled (RSN0402)
/ Resproly Biopharma
- LARVOL DELTA
Home
Next
Prev
1 to 2
Of
2
Go to page
1
July 08, 2024
A Study to Evaluate Safety, Tolerability and Pharmacokinetics of RSN0402 in Healthy Volunteers
(clinicaltrials.gov)
- P1 | N=72 | Recruiting | Sponsor: Shenzhen Resproly Biopharmaceutical Co., Ltd | Not yet recruiting ➔ Recruiting
Enrollment open • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases
July 01, 2024
A Study to Evaluate Safety, Tolerability and Pharmacokinetics of RSN0402 in Healthy Volunteers
(clinicaltrials.gov)
- P1 | N=72 | Not yet recruiting | Sponsor: Shenzhen Resproly Biopharmaceutical Co., Ltd
New P1 trial • Fibrosis • Idiopathic Pulmonary Fibrosis • Immunology • Pulmonary Disease • Respiratory Diseases
1 to 2
Of
2
Go to page
1